EMD Serono launches male fertility education campaign

Share this article:
EMD Serono launches male fertility education campaign
EMD Serono launches male fertility education campaign
EMD Serono is partnering with Men's Health Network on a patient education campaign aimed at raising awareness of male infertility.

The effort, dubbed “In The Know: What No One Tells You About Male Fertility,” is launching this week, which is Men's Health Week. The campaign features a 20-page booklet written in conjunction with the Society for the Study of Male Reproduction, a website (www.FertilityLifeLines.com/intheknow) and a PR campaign by Baer Consulting. It's being supported by a satellite media tour, and aimed at reaching couples through health titles and local news outlets.

FertilityLifeLines.com is EMD Serono's fertility awareness site, and includes branding for Gonal-f, a hormone treatment indicated for both male and female infertility. Patients can get the booklet by registering at the site or by calling a toll-free number. EMD Serono reps are distributing copies to reproductive endocrinologists, and the company is promoting it online through search engine optimization and banner ads. 

As part of the effort, EMD Serono and Men's Health Network are touting a survey finding that 45% of men say they would wait a year or more to seek treatment for an infertility problem. Men are much less likely to present than women, said EVP, endocrinology David Stern, and for women in their late 30s and older, time is critical.

"Some of this is embarassment," said Stern. "It's important to talk about it. It's not something that makes you less manly. It's common and can be treated."

About one in eight couples – around 7.3 million Americans -- has trouble conceiving, the company said, and half of those cases have to do with male fertility issues – often easily treatable ones.  

The campaign grew out of an earlier “girlfriend-to-girlfriend” effort, aimed at women and based on research conducted with Conceive Magazine, that launched last year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...